Y-mAbs Therapeutics (NASDAQ: YMAB)
Y-mAbs Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Y-mAbs Therapeutics Company Info
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
News & Analysis
2 Biotech Stocks With Major Incoming Catalysts
While everyone's focused on COVID-19, these drugmakers are looking forward to unrelated FDA approvals that could push their stock prices into the clouds.
Should You Own This Sleeper Biotech Stock?
This cancer-fighting biotech could have two approved drugs in the next year, and a whole lot more.
Valuation
Earnings Transcripts
YmAbs Therapeutics, Inc. (YMAB) Q3 2020 Earnings Call Transcript
YMAB earnings call for the period ending September 30, 2020.
YmAbs Therapeutics, Inc. (YMAB) Q2 2020 Earnings Call Transcript
YMAB earnings call for the period ending June 30, 2020.
YmAbs Therapeutics, Inc. (YMAB) Q1 2020 Earnings Call Transcript
YMAB earnings call for the period ending March 31, 2020.
YmAbs Therapeutics, Inc. (YMAB) Q4 2019 Earnings Call Transcript
YMAB earnings call for the period ending December 31, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.